• / Free eNewsletters & Magazine
  • / My Account
Home>Not an Entry Point for U.S. Stocks

Not an Entry Point for U.S. Stocks

Morningstar Articles

Mon, 12 Aug 2013

Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for

Related Videos

  1. Retirees: Learn From the Recent Bond Turbulence

    How investors can use the recent interest-rate-driven disruption as a stress-test for their portfolios. Plus, a new retirement income tool and some good news on prescription-drug costs.

©2017 Morningstar Advisor. All right reserved.